Arturo Cedeno Llorens, MD
Pulmonary Disease · Aguadilla, PRNPI 1679577399
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 115 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by AstraZeneca at 42.3% of the total.
Across 115 payments — averaging $30.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- GSK$433
- Boehringer Ingelheim$421
- Merck$291
- Johnson & Johnson$289
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$94
- plus $517 from 10 others
What the payments were for
- Food & beverage$3,538100%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 55 | $1,498 |
| GSK | 27 | $433 |
| Boehringer Ingelheim | 7 | $421 |
| Merck | 8 | $291 |
| Johnson & Johnson | 5 | $289 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $94 |
| Boston Scientific | 1 | $83 |
| Mallinckrodt Enterprises LLC | 1 | $83 |
| Dexcom, Inc. | 1 | $79 |
| Pfizer | 1 | $75 |
| Jazz Pharmaceuticals Inc. | 1 | $63 |
| PBG Puerto Rico LLC | 2 | $44 |
| Mallinckrodt Hospital Products Inc. | 1 | $34 |
| Shire North American Group Inc | 1 | $23 |
| Chiesi USA, Inc. | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,543 in reported general payments places this provider in the 60th percentile of 138 pulmonary disease providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 11 | $144,508 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 124 | $82,641 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 221 | $63,049 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 75 | $48,626 |
| Breo ElliptaFluticasone/Vilanterol | 95 | $39,693 |
| Spiriva RespimatTiotropium Bromide | 68 | $36,214 |
| SymbicortBudesonide/Formoterol Fumarate | 115 | $27,432 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 54 | $26,435 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 575 | $25,511 |
| Wixela InhubFluticasone Propion/Salmeterol | 152 | $24,339 |
| Fluticasone Propionate HfaFluticasone Propionate | 64 | $20,244 |
| Spiriva HandihalerTiotropium Bromide | 21 | $10,838 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 20 | $9,206 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 49 | $6,349 |
| Arnuity ElliptaFluticasone Furoate | 27 | $5,705 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $421 | $207,157133 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $433 | $137,245266 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,498 | $76,058190 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 138 pulmonary disease providers in Puerto Rico.
Other pulmonary disease in Aguadilla
- Alvaro Aranda RodriguezGuaynabo$725K
- Luis Garcia BarretoCoamo$393K
- Luis Nieves GarrasteguiRio Piedras$121K
- Jahaira Serrano DominguezArecibo$102K
- William Villanueva-BosqueArecibo$67K
- Domingo Chardon FelicianoPonce$45K
- Joel Nieves ScharonSan Juan$43K
- George FahedPonce$16K
- Luis Gerena MontanoSan Juan$15K
- Rafael Franjul JuliaoSan Juan$15K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.